title: Furosemide and 11beta-hydroxysteroid dehydrogenase activity, in man.
abstract: Mineralocorticoid receptors possess the same affinity for aldosterone and for cortisol and preferential binding of aldosterone is modulated by the 11 beta-hydroxysteroid dehydrogenase (11 beta-OHSD) enzyme, which converts cortisol to its inactive metabolite cortisone. Several endogenous or exogenous compounds able to inhibit the enzyme have been described and, as a consequence, produce the syndrome of apparent mineralocorticoid excess (AME) characterized by hypertension, hypokalemia, volume repletion and suppression of the renin-angiotensin-aldosterone system. High doses of furosemide, a diuretic that works in the luminal surface of the thick ascending limb of Henle's loop, have been reported to inhibit 11 beta-OHSD activity to the same extent as licorice in vivo and in vitro, in rat. The aim of our study was to verify the effect of the drug on 11 beta-OHSD activity in man at the doses currently used in clinical practice. We tested the activity of 11 beta-OHSD following both acute and protracted administration of furosemide. In the acute study, the drug was administered at low (40 mg i.v. in bolo) and high doses (infusion of 10 mg/kg bw i.v for six hours); the protracted furosemide administration consisted in 50 mg/day for 20 days, by mouth. The ratios between the cortisol metabolites tetrahydrocortisol plus allo-tetrahydrocortisol to tetra-hydrocortisone and urinary free cortisol to urinary free cortisone were used to measure the activity of 11 beta-OHSD. Urinary cortisol, cortisone and their metabolites were tested by a gas-chromatographic/mass spectrometric method. Neither acute nor prolonged administration of furosemide did affect the activity of 11 beta-OHSD although the drug was able to modify plasma aldosterone and PRA secretion and to determine hypokalemia. Our results suggest that furosemide does not play a significant role in 11 beta-OHSD modulation in humans, at least at the dosage used in clinical practice.
authors.affiliation: Institute of Endocrinology, University of Sassari, Sassari, Italy. mariocp@tin.it
authors.forename: M
authors.initials: M
authors.lastname: Palermo
authors.forename: D
authors.initials: D
authors.lastname: Armanini
authors.forename: C H L
authors.initials: CH
authors.lastname: Shackleton
authors.forename: G
authors.initials: G
authors.lastname: Sorba
authors.forename: M
authors.initials: M
authors.lastname: Cossu
authors.forename: E
authors.initials: E
authors.lastname: Roitman
authors.forename: C
authors.initials: C
authors.lastname: Scaroni
authors.forename: G
authors.initials: G
authors.lastname: Delitala
mesh_terms: D042842:11-beta-Hydroxysteroid Dehydrogenases; D000450:Aldosterone / Q000097:blood; D003348:Cortisone / Q000652:urine; D004305:Dose-Response Relationship, Drug; D005665:Furosemide / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000652:urine; D006913:Hydroxysteroid Dehydrogenases / Q000378:metabolism*; D008297:Male; D012083:Renin / Q000097:blood / Q000187:drug effects
chemical_list: D000450:Aldosterone; D005665:Furosemide; D006913:Hydroxysteroid Dehydrogenases; D042842:11-beta-Hydroxysteroid Dehydrogenases; D012083:Renin; D003348:Cortisone; D006854:Hydrocortisone